Tag: hemophilia A
Takeda launches advanced treatment for hemophilia A patients
An extended half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A, resulting in lower weekly infusion rates than standard FVIII, providing excellent prophylactic coverage